380 related articles for article (PubMed ID: 36847998)
1. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
Kaye KS; Naas T; Pogue JM; Rossolini GM
Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
5. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms.
Wu JY; Srinivas P; Pogue JM
Infect Dis Ther; 2020 Mar; 9(1):17-40. PubMed ID: 32072491
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
[TBL] [Abstract][Full Text] [Related]
8. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
Bhowmick T; Weinstein MP
Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
[TBL] [Abstract][Full Text] [Related]
9. Reviewing novel treatment options for carbapenem-resistant
Mackow NA; van Duin D
Expert Rev Anti Infect Ther; 2024; 22(1-3):71-85. PubMed ID: 38183224
[TBL] [Abstract][Full Text] [Related]
10. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
11.
Longshaw C; Manissero D; Tsuji M; Echols R; Yamano Y
JAC Antimicrob Resist; 2020 Sep; 2(3):dlaa060. PubMed ID: 34223017
[TBL] [Abstract][Full Text] [Related]
12.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
13. Clonal dissemination of
Bovo F; Amadesi S; Palombo M; Lazzarotto T; Ambretti S; Gaibani P
JAC Antimicrob Resist; 2023 Aug; 5(4):dlad099. PubMed ID: 37600494
[TBL] [Abstract][Full Text] [Related]
14. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
16. Infections Caused by Carbapenem-Resistant
Sheu CC; Chang YT; Lin SY; Chen YH; Hsueh PR
Front Microbiol; 2019; 10():80. PubMed ID: 30761114
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
18. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
